Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly

Blood-based biomarkers related to immune- and neuroregulatory processes may be indicative of dementia but lack standardization and proof-of-principle studies. The blood serum collection protocol as well as the analytic procedure to quantify the markers BDNF, IGF-1, VEGF, TGF-β 1, MCP-1 and IL-18 in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neurodegenerative disease management Ročník 9; číslo 4; s. 193 - 203
Hlavní autoři: Schipke, Carola G, Günter, Oliver, Weinert, Christina, Scotton, Patrick, Sigle, Jörg-Peter, Kallarackal, Jim, Kabelitz, Dieter, Finzen, Asmus, Feuerhelm-Heidl, Annegret
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Future Medicine Ltd 01.08.2019
Témata:
Aging
Alzheimer's disease
biomarker
Biomarkers
Blood & organ donations
blood serum
clinical diagnosis
Cytokines
Dementia
inflammation
Laboratories
Medical diagnosis
Neurodegeneration
Older people
Patients
Proteins
Standardization
Stem cells
Stroke
Studies
clinical diagnosis
Alzheimer’s disease
inflammation
blood serum
neurodegeneration
dementia
cytokines
biomarker
ISSN:1758-2024, 1758-2032, 1758-2032
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Blood-based biomarkers related to immune- and neuroregulatory processes may be indicative of dementia but lack standardization and proof-of-principle studies. The blood serum collection protocol as well as the analytic procedure to quantify the markers BDNF, IGF-1, VEGF, TGF-β 1, MCP-1 and IL-18 in blood serum were standardized and their concentrations were compared between groups of 81 Alzheimer’s disease patients and 79 healthy controls. Applying standardized methods, results for the quantification of the six markers in blood serum are stable and their concentrations significantly differ for all analytes except VEGF between patients diagnosed with Alzheimer’s disease and healthy controls. Analyzing a panel of six markers in blood serum under standardized conditions may serve as a diagnostic tool in primary dementia care in the future. Neurodegenerative processes underlie and account for a large portion of dementia cases in the elderly, with Alzheimer’s disease being the most common neurodegenerative disorder. Yet, it is challenging for nonspecialized physicians to assess whether a patients’ cognitive impairment originates in underlying neurodegenerative processes. We show that the combination of six biomarkers quantified in blood can indicate the presence of Alzheimer’s disease, since these markers are not altered in healthy elderly people. Blood biomarkers indicative of neurodegenerative processes may be useful in the future to compile a personalized diagnostic and treatment plan to assess the basis of, and properly treat, cognitive impairment.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1758-2024
1758-2032
1758-2032
DOI:10.2217/nmt-2019-0003